Anti-proliferative and pro-apoptotic effects of 3,3'-diindolylmethane in human cervical cancer cells

Zhu,Junyong; Li,Yuan; Guan,Chao; Chen,Zuhua

doi:10.3892/or.2012.1877

Anti-proliferative and pro-apoptotic effects of 3,3'-diindolylmethane in human cervical cancer cells

Authors:
- Junyong Zhu
- Yuan Li
- Chao Guan
- Zuhua Chen
View Affiliations

Affiliations: Department of Gynecology, Renmin Hospital of Wuhan University, Wuchang, Wuhan 430060, P.R. China
Published online on: June 20, 2012 https://doi.org/10.3892/or.2012.1877
Pages: 1063-1068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The antitumor effects of Indo-3-carbinol (I3C) have been proven in many human carcinoma cells. However, the roles of 3,3-diindolylmethane (DIM), an important polymer converted from I3C under pH 5.0-7.0, on the growth and proliferation of cervical cancer HeLa and SiHa cells still remain unrevealed. In the present study, we investigated the potential anti-proliferative and pro-apoptotic effects of DIM on HeLa and SiHa cells. Cell proliferation was detected by Cell Counting kit-8 and apoptosis was analyzed by flow cytometry. In addition, morphological changes accompanying cell apoptosis were observed using an inverted microscope after Hoechst 33258 staining. In addition, expression changes of proteins involved in the MAPK and PI3K pathways were determined by western blotting. DIM treatment inhibited the proliferation and induced apoptosis of HeLa and SiHa cells significantly in a time- and dose-dependent manner. Moreover, SiHa cells were more sensitive to DIM treatment than HeLa cells (P<0.05). In addition, the expression of ERK, p38 and p-p38, which are involved in the MAPK pathway, was downregulated by DIM treatment. Another protein involved in the MAPK pathway, JNK, was upregulated. Furthermore, DIM treatment significantly suppressed the expression of Akt, p-Akt, PI3K p110α, PI3K p110β, PI3K class III, GSK3-β, p-PDK1 and p-c-Raf which are involved in the PI3K pathway. These results demonstrate that DIM exerts antitumor effects on HeLa and SiHa cells through its anti-proliferative and pro-apoptotic roles, especially for SiHa cells. The molecular mechanism for these effects may be related to its regulatory effects on MAPK and PI3K pathway and apoptosis proteins. DIM may be a preventive and therapeutic agent against cervical cancer.

View Figures

View References

1	Newall AT, Beutels P, Wood JG, Edmunds WJ and MacIntyre CR: Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 7:289–296. 2007. View Article : Google Scholar : PubMed/NCBI
2	Tanaka T, Bai T, Yukawa K and Umesaki N: Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 15:939–947. 2006.PubMed/NCBI
3	Sarkar FH, Li Y, Wang Z and Kong D: Cellular signaling perturbation by natural products. Cell Signal. 21:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
4	Brew CT, Aronchik I, Hsu JC, et al: Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer. 118:857–868. 2006. View Article : Google Scholar : PubMed/NCBI
5	Chinni SR, Li Y, Upadhyay S, Koppolu PK and Sarkar FH: Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 20:2927–2936. 2001. View Article : Google Scholar : PubMed/NCBI
6	Rahman KM, Aranha O, Glazyrin A, Chinni SR and Sarkar FH: Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene. 19:5764–5771. 2000. View Article : Google Scholar : PubMed/NCBI
7	Cover CM, Hsieh SJ, Tran SH, et al: Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 273:3838–3847. 1998. View Article : Google Scholar
8	Fan S, Wang J, Yuan R, et al: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 284:1354–1356. 1999. View Article : Google Scholar : PubMed/NCBI
9	Meng Q, Qi M, Chen DZ, et al: Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J Mol Med. 78:155–165. 2000. View Article : Google Scholar : PubMed/NCBI
10	Chang X, Tou JC, Hong C, et al: 3,3′-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis. 26:771–778. 2005.
11	Safe S, Papineni S and Chintharlapalli S: Cancer chemotherapy with indole-3-carbinol, bis(3′-indolyl)methane and synthetic analogs. Cancer Lett. 269:326–338. 2008.
12	Khwaja FS, Wynne S, Posey I and Djakiew D: 3,3′-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res. 2:566–571. 2009.
13	Chinnakannu K, Chen D, Li Y, et al: Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol. 219:94–99. 2009.
14	Ge C, Xu J and Jiao Y: New derivatives I3C-6 of indole-3-carbinol in cervical cancer HeLa cells. Suzhou University J Med Sci. 29:838–834. 2009.
15	Chang YC, Riby J, Chang GH, Peng BC, Firestone G and Bjeldanes LF: Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol. 58:825–834. 1999.PubMed/NCBI
16	Zhou Y, Feng Y and Zhang X: Study on the effect of artesunate combined with irradiation on DNA damage of HeLa and SiHa cells of human cervical cancer. J Radiat Res Radiat Process. 29:33–36. 2011.
17	Wang H, Zhang Y and Jiang K: Enhancement of photodynamic therapy sensitivity by cisplatin in human cervical carcinoma cell lines. J Xian Jiaotong University (Med Sci ). 31:625–630. 2010.
18	Han B, Toyomasu T and Shinozawa T: Induction of apoptosis in cultured cells by extracts from shiitake (Lentinula edodes) mycelial culture broth. Mycoscience. 41:623–631. 2000. View Article : Google Scholar
19	Fecher LA, Amaravadi RK and Flaherty KT: The MAPK pathway in melanoma. Curr Opin Oncol. 20:183–189. 2008. View Article : Google Scholar
20	Seger R and Krebs EG: The MAPK signaling cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
21	Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol. 71:479–500. 1999. View Article : Google Scholar
22	Meira DD, de Almeida VH, Mororo JS, et al: Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer. 101:782–791. 2009. View Article : Google Scholar : PubMed/NCBI
23	Inamdar GS, Madhunapantula SV and Robertson GP: Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 80:624–637. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lopez-Bergami P, Huang C, Goydos JS, et al: Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 11:447–460. 2007. View Article : Google Scholar : PubMed/NCBI
25	Mirmohammadsadegh A, Mota R, Gustrau A, et al: ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 127:2207–2215. 2007. View Article : Google Scholar : PubMed/NCBI
26	Flaherty KT: Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther. 7:617–626. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sharma A, Tran MA, Liang S, et al: Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 66:8200–8209. 2006. View Article : Google Scholar
28	Greenberg AK, Basu S, Hu J, et al: Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 26:558–564. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kim MS, Lee EJ, Kim HR and Moon A: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 63:5454–5461. 2003.PubMed/NCBI
30	Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV and Cowell JK: WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res. 308:135–145. 2005. View Article : Google Scholar : PubMed/NCBI
31	Huang X, Chen S, Xu L, et al: Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65:3470–3478. 2005.PubMed/NCBI
32	Zwang Y and Yarden Y: p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J. 25:4195–4206. 2006. View Article : Google Scholar
33	Lin A: A five-year itch in TNF-alpha cytotoxicity: the time factor determines JNK action. Dev Cell. 10:277–278. 2006.PubMed/NCBI
34	Bowen C, Birrer M and Gelmann EP: Retinoblastoma protein-mediated apoptosis after gamma-irradiation. J Biol Chem. 277:44969–44979. 2002. View Article : Google Scholar : PubMed/NCBI
35	Li T, Dai W and Lu L: Ultraviolet-induced junD activation and apoptosis in myeloblastic leukemia ML-1 cells. J Biol Chem. 277:32668–32676. 2002. View Article : Google Scholar : PubMed/NCBI
36	Ouwens DM, Gomes de Mesquita DS, Dekker J and Maassen JA: Hyperosmotic stress activates the insulin receptor in CHO cells. Biochim Biophys Acta. 1540:97–106. 2001. View Article : Google Scholar : PubMed/NCBI
37	Stadheim TA and Kucera GL: c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res. 26:55–65. 2002. View Article : Google Scholar : PubMed/NCBI
38	Liao Y and Hung MC: Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol. 23:6836–6848. 2003. View Article : Google Scholar : PubMed/NCBI
39	Garrett JT, Chakrabarty A and Arteaga CL: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2:1314–1321. 2011.PubMed/NCBI
40	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
41	Blain SW and Massague J: Breast cancer banishes p27 from nucleus. Nat Med. 8:1076–1078. 2002. View Article : Google Scholar : PubMed/NCBI
42	Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 4:648–657. 2002. View Article : Google Scholar : PubMed/NCBI
43	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
44	Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
45	Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21^Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 3:245–252. 2001. View Article : Google Scholar : PubMed/NCBI
46	Brugge J, Hung MC and Mills GB: A new mutational AKTivation in the PI3K pathway. Cancer Cell. 12:104–107. 2007. View Article : Google Scholar : PubMed/NCBI
47	Ma JL, Lee SJ, Duong JK and Stern DF: Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1. J Biol Chem. 281:3954–3963. 2006. View Article : Google Scholar : PubMed/NCBI
48	Xu J, Gao M, Fan S, et al: Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells. Oncogene. 26:2925–2938. 2007. View Article : Google Scholar : PubMed/NCBI
49	Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 15:429–440. 2009. View Article : Google Scholar : PubMed/NCBI
50	Xie L, Chen X and Liu Q: Study of PI3K p110α expression in cervical lesions. Pract Prev Med. 18:2011.
51	Shankar S and Srivastava RK: Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 30:905–918. 2007.
52	Barnes NL, Warnberg F, Farnie G, et al: Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer. 96:575–582. 2007. View Article : Google Scholar : PubMed/NCBI
53	de Marsh RW, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr and Benson AB III: A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 30:26–31. 2007.
54	Cirstea D, Hideshima T, Rodig S, et al: Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 9:963–975. 2010. View Article : Google Scholar
55	Floryk D and Thompson TC: Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett. 266:216–226. 2008. View Article : Google Scholar : PubMed/NCBI
56	Zhang M, Fang X, Liu H, Wang S and Yang D: Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP). Biochem Pharmacol. 73:15–24. 2007. View Article : Google Scholar : PubMed/NCBI